Related references
Note: Only part of the references are listed.Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients
Frederic Baron et al.
HAEMATOLOGICA (2020)
The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation
Arnon Nagler et al.
LEUKEMIA (2020)
Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia
Klaus Wethmar et al.
BONE MARROW TRANSPLANTATION (2020)
Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML
Linde M. Morsink et al.
LEUKEMIA (2020)
Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukemia: Long-term follow up of a phase III study
Frederic Baron et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Impact of detectable measurable residual disease on umbilical cord blood transplantation
Frederic Baron et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Catherine J. Lee et al.
BONE MARROW TRANSPLANTATION (2019)
Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse
Richard D. Press et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome
Thierry Guillaume et al.
BONE MARROW TRANSPLANTATION (2019)
MRD in AML: The Role of New Techniques
Maria Teresa Voso et al.
FRONTIERS IN ONCOLOGY (2019)
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
Adriano Venditti et al.
BLOOD (2019)
Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
Irene Della Starza et al.
FRONTIERS IN ONCOLOGY (2019)
The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia
Anna Czyz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT
Jiri Pavlu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT
Christoph Schmid et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype
Frederic Baron et al.
HAEMATOLOGICA (2019)
Minimal residual disease and stem cell transplantation outcomes
Jacqueline Cloos et al.
Hematology-American Society of Hematology Education Program (2019)
Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation
Maria H. Gilleece et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations
Sylvie D. Freeman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
Felicitas Thol et al.
BLOOD (2018)
Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Jonathan Canaani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia
Prisca Theunissen et al.
BLOOD (2017)
Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia
Betul Oran et al.
HAEMATOLOGICA (2017)
Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia
Betul Oran et al.
HAEMATOLOGICA (2017)
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Sarah A. Buckley et al.
HAEMATOLOGICA (2017)
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group
Marie Balsat et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Sarah A. Buckley et al.
HAEMATOLOGICA (2017)
Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects
Gregory Ehx et al.
ONCOIMMUNOLOGY (2017)
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia AMeta-analysis
Donald A. Berry et al.
JAMA ONCOLOGY (2017)
Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia
Y. Zhou et al.
LEUKEMIA (2016)
Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 Trial
Peter Bader et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol
Virginie Gandemer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
Roland B. Walter et al.
BLOOD (2013)
Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression
Sarah Pozzi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
Jan Kroenke et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Share Paper
